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Background: This research elucidates the question of whether common and widespread dental procedures (DP)
like root filling (RF) and the removal of wisdom teeth (WT) contribute to chronic inflammation in the jawbone.
Dentists, in carrying out these DP, can set off defective wound healing in the jawbone in ignorance of its connection
to inflammatory mediators and the possibility of it being a hidden cause of chronic systemic diseases (SYD).
Materials and methods: We examined samples of the jawbone for seven cytokines by multiplex analysis in three
groups of jawbone areas. In order to clarify systemic interrelations, specimens from 16 patients were analyzed in
areas of former surgery in the retromolar wisdom tooth area; specimens from 16 patients were analyzed in the
jawbone, apically of teeth with RF; and specimens from 19 patients were of the healthy jawbone. Each of the
retromolar and the apical jawbone samples showed clinically fatty degenerated and osteonecrotic medullary changes.
Results: All fatty necrotic and osteolytic jawbone (FDOJ) samples showed regulated on activation, normal T-cell
expressed and secreted (RANTES) and fibroblast growth factor (FGF)-2 as the only extremely overexpressed cytokines.
FDOJ cohorts showed a 30-fold mean overexpression of RANTES and a 20-fold overexpressed level of FGF-2 when
compared to healthy controls.
Conclusions: As RANTES is discussed in the literature as a possible contributor to inflammatory diseases, and though
it might have oncogenic effects, we hypothesize that FDOJ in areas of improper and incomplete wound healing in
the jawbone might act as hyperactivated signaling pathways, while serving as an unknown source of “silent
inflammation”. Because of the wide range of RANTES in immune diseases, treating FDOJ can cover many
potential prediction or prognosis of individual outcomes.
Keywords: Chronic inflammation in the jawbone, Fatty necrotic osteolytic jawbone, Hyperactivated signaling
pathways, RANTES/CCL5, Predictive preventive personalized medicineOverview
Acute disease is unavoidable given our interaction with
dental decay, but it is just the tip of a disease iceberg.
Below the surface lie hidden chronic diseases (cancer,
autoimmune diseases, etc.), the products of an immune
system that is being constantly triggered by overex-
pressed cytokines. These triggers lead to the stimulation* Correspondence: drlechner@aol.com
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article, unless otherwise stated.of different signaling pathways, which are instrumental
in the development of chronic disease. In general, the
cell communication systems are organized as cascades in
sequential stages [1]. The signal messengers, like the
cytokines, carry instructions that are received by cells
with specific receptors, which are able to detect them.
Most dental procedures consist in eliminating acute in-
flammation in situations that do not feature typical signs
of inflammation like pain and tissue swelling. This is the
case with root fillings (RF) and surgical procedures like
wisdom tooth surgery (WTS). The use of antibioticsed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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after dental procedures and during acute infections (AIs)
in daily practice. This research tries to elucidate the con-
version of AI into chronic inflammation (CI) in the jaw-
bone during common dental procedures like RF and
WTS. In daily dental practice, the effects of CI on over-
all health are normally not of interest because local
problems seem to be resolved after the symptoms of AI
are gone. Here, we try to define the characteristics of CI
by reference to the possible cytokine content of fatty de-
generative osteonecrotic jawbone (FDOJ) found in old
WTS extraction or RF operation sites with insufficient
wound healing (IWH). Our hypothesis is that the reduc-
tion of AI might serve as the beginning of a possible de-
velopment of CI in the jawbone. Persons with certain
risk factors might be prone to developing subsequent
systemic diseases (SYD). Treatments tailored to the per-
son and individually targeted prevention is a crucial part
of this therapeutic concept.
Methods
Groups of patients examined
In this study, we focused on IWH in former wisdom
tooth areas that were mostly in danger of developing AI
following dental surgery in a group of patients with
rheumatoid arthritis (RA) (number [n] = 16). The inclu-
sion criteria for the studied population with RA were
(1) patients with clinical symptoms of joint pain, (2) a
diagnosis of “rheumatoid arthritis” as determined by in-
ternal doctors, and (3) a local diagnosis of FDOJ in the
jawbone in retromolar areas with former WTS. Demo-
graphic data of the RA/WTS cohort were as follows: an
average age of 56 years (standard deviation [SD] = 11.4
years) and a gender ratio of 8:8 (females/males). We also
focused on areas of the jawbone underneath RF in a
group of patients with the following SYD (n = 16):
RA = 6; neurodegenerative diseases like chronic fa-
tigue syndrome and amyotrophic lateral sclerosis = 4;
allergies = 2; breast cancer (BC) = 2; and Hashimoto’s
thyroiditis = 2. The inclusion criteria of the studied
cohort with root-filled tooth (RFT) included patients
with systemic immunological or neurodegenerative dis-
eases and a local diagnosis of FDOJ in the jawbone, api-
cally, of one RF. Demographic data of the RF/SYD cohort
included an average age of 60 years (SD = 13.2 years) and
a gender ratio of 14:1 (females/males).
We collected tissue samples from these 32 patients
(RA/WTS group = 16; RF/SYD group = 16) from FDOJ
regions. Mandatory inclusion criteria for both groups
were the availability of two-dimensional orthopantomo-
grams (2D-OPG), cone beam 3D-DVT, and measure-
ment of the bone density of the jawbone with
transalveolar ultrasound (TAU) technology. TAU is a
useful tool when establishing FDOJ [2].The third cohort was a group of patients with samples
of the healthy jawbone (HJB), which were taken in the
form of drill cores during normal dental implantation
surgery. Inclusion criteria for this group were no radio-
logically distinctive feature in 2D-OPG and incon-
spicuous TAU measurements of bone density in the
implantation range. The age range of the control group
consisting of 19 patients without FDOJ was 38–71 years,
with an average age of 54 years (SD = 12.4 years), and there
was a gender ratio (female/male) of 11/8.
The taking by patients of any medications due to sys-
temic complaints did not serve as an exclusion criterion.
Use of bisphosphonate medication was the central exclu-
sion criterion for all three groups. The research was
based on data retrieved from patients during normal
dental surgery. All patients gave their written informed
consent. This study was performed as a randomized
controlled trial. Statistical analyses were performed
using IBM SPSS, version 19 (IBM Corporation, Armonk,
NY, USA).
Clinical features of fatty degenerative jawbone definition
and diagnostic criteria
The softening in FDOJ bone marrow is so distinct that
the marrow space can actually be sucked and spooned
out. Hollow cavitations with fatty degenerated adipocytes
have undergone dystrophic changes, accompanied by de-
myelination of the bony sheath of the infra-alveolar
nerve. All 32 FDOJ samples in the wisdom tooth (WT)
and RF groups presented themselves clinically and
macroscopically as fatty lumps. Figure 1 shows a type of
specimen with a predominantly fatty transformation of
the jawbone in the left part. The often impressive extent
of FDOJ lesions is documented in the right part by X-ray
with a contrast medium.
To obtain a better understanding of this marrow
disorder, Figure 2 shows a characteristic photomicro-
graph of FDOJ lesions. Following previous research
[3], it can be seen that FDOJ is a similar lesion to
those found in the long bones, which are primarily
defined by bone marrow edema and chronic nonsup-
purative osteomyelitis.
Sampling of FDOJ tissue
Current treatment of the FDOJ lesion consists of curet-
tage of the bony cavity [4,5]. To elucidate the cytokine
patterns in the jawbone in the corresponding author’s
Clinic for Integrative Dentistry, 32 patients diagnosed
with FDOJ in sites of former WTS or in the apical area
of RFT had surgery on the affected area of the jaw. Fol-
lowing local anesthesia and the folding of a mucoperios-
tal flap, the cortical layer was removed. All patients
showed FDOJ inside the bone marrow, which was quite
similar to the samples described in literature [6,7] and as
Fatty-degenerative medullary spongial bone -  
necrotic adipocytes form yellow osteolytic and 
softened tissue. 
Contrast medium 
Figure 1 FDOJ sample of fatty and osteolytic degenerated bone marrow (left part) and a contrast medium in the FDOJ cavity after curettage
(right part).
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formed on edentulous jaw areas in the regions of former
WT, adjacent retromolar areas, or the area underneath
teeth with root fillings. The FDOJ samples with a volume
up to 0.5 cm3 were stored in a dry, sterile, 2-mL collecting
vial (Sarstedt AG & Co., Nümbrecht, Germany), which
was made airtight, and frozen at −20°C.
Processing of necrotic tissue samples and measurement
of cytokines
At the examining Institute for Medical Diagnostics,
Nikolaistr. 22, D-12247 Berlin (inspected by DAKKS
[Deutsche Akkreditierungsstelle GmbH; accredited toFigure 2 Photomicrograph of an FDOJ lesion with typical signs of
osteonecrosis and fatty degenerated and necrobiotic adipocytes,
centered in a hollow cavitation of the jawbone. The red circle shows
fatty degenerated and necrobiotic adipocytes centered in a hollow
cavitation of the jawbone with clear signs of osteonecrosis (1:200).DIN EN ISO/IEC 17025:2005 and DIN EN ISO
15189:2007]), the samples were homogenized by mech-
anical force in 200 μL of cold protease inhibitor buffer
(Complete Mini Protease Inhibitor Cocktail; Roche
Diagnostics GmbH, Penzberg, Germany). The homogen-
ate was centrifuged for 15 min at 13,400 rpm. After-
wards, the supernatant was collected and centrifuged for
a further 25 min at 13,400 rpm. In the 15 supernatants
of tissue homogenate, we measured regulated on activa-
tion, normal T-cell expressed and secreted (RANTES),
fibroblast growth factor (FGF)-2, interleukin (IL)-1 re-
ceptor antagonist (ra), IL-6, IL-8, monocyte chemotactic
protein-1 (MCP1), and tumor necrosis factor-alpha
(TNF-α). Measurement was performed using the Human
Cytokine/Chemokine Panel I (MPXHCYTO-60K; Merck
KGaA, Darmstadt, Germany) according to the manufac-
turer’s instructions, and these findings were analyzed
using the Luminex® 200™ with xPonent® Software (Luminex
Co, Austin, TX, USA).
Results of seven cytokine panel evaluations in the
osteonecrotic and healthy jawbone
The mean values of 19 samples of HJB were as follows
(pg/mL): FGF-2, 27.6; IL-1ra, 196.5; IL-6, 101.0; IL-8,
7.5; MCP-1, 20.3; TNF-α, 11.0; RANTES, 149.9 (see
Figure 3). Values for healthy patients and HJB were
not available for comparison from the literature.
Expression of seven cytokines in the wisdom tooth area
of the jawbone in 16 patients with rheumatoid arthritis
The results of the multiplex analysis of the seven cytokines
in the WTS/RA cohort (n = 16) are shown in Figure 3,
and they were compared to the mean values of HJB.
WTS/RA patients show elevated inflammatory signals in
.7,6






















Figure 3 Distribution of seven cytokines in HJB (n = 19) (pg/mL) and in FDOJ (n = 16).
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ous IWH in the jawbone with an average RANTES/CCL5
value of 4.297,4 pg/mL (SD = ±2,145.7) when compared to
that of the randomized controlled sample of 149.9 pg/mL
in HJB. All other cytokines—except FGF-2 and IL-
1ra—were not derailed. The most striking result of this
analysis is the high concentration of RANTES. No other
proinflammatory messengers, such as IL-6, IL-8, MCP-1,
or TNF-α, were detected at such elevated levels from
the jawbones of a group of patients with former




Figure 4 FDOJ sample from the former area of WTS with focal loss of med
osteoporotic marrow defect. Single bony trabeculae protrude from the sofCase report: RANTES overexpression in the jawbone in
the former wisdom tooth area
The FDOJ sample in Figure 4 was removed from a
36-year-old patient; her right shoulder had been
treated with cortisone injections because of RA. The
picture shows the FDOJ sample after surgery in the
right lower wisdom tooth area, with focal loss of the
medullary bone structure, with ischemic and fatty
changes in the remaining osteoporotic marrow defect.
Single bony trabeculae protrude from the softened
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ullary bone structure, as well as fatty changes in the remaining
tened and yellowish altered surrounding marrow tissue.
Lechner and von Baehr The EPMA Journal  (2015) 6:10 Page 5 of 9the columns in the right image, multiplex analysis of
this FDOJ sample indicated a 15-fold overexpression
of RANTES in the retromolar area with former WTS
when compared to HJB. Inflammatory pain in the pa-
tient’s right shoulder disappeared shortly after curet-
ting this FDOJ.
Expression of seven cytokines in the apical area of
root-filled teeth in the jawbone
The results of the multiplex analysis of the seven cytokines
in the RFT/SYD cohort (n = 16) are shown in Figure 5 and
compared to mean values of HJB. RFT/SYD patients show
elevated inflammatory signals in the FDOJ samples that are
derived from the RFT areas, and obvious IWH is evident in
the jawbone with an average RANTES/CCL5 value of
4,953.1 pg/mL (SD = ±2,645.2) when compared to that of
the randomized controlled sample of 149.9 pg/mL in HJB.
All other cytokines—except FGF-2 and IL-1ra—were not
derailed. The most striking result of this analysis is the high
concentration of RANTES. No other proinflammatory
messengers, such as IL-6, IL-8, MCP-1, or TNF-α, were
detected at such elevated levels.
Case report: RANTES overexpression in the jawbone
underneath a root-filled tooth
In order to document the noncoincidental representation
of FDOJ in normal dental 2D-OPG and to determine the
intramedullary extent of FDOJ, we injected a contrast
agent into the FDOJ area after curetting the softened
cancellous bone underneath the previously extracted RFT
(see Figure 6). The upper X-ray shows the same area with27.6
196.5 101.0 7.5 20.3








Figure 5 Distribution of seven cytokines in HJB (n = 19) (pg/mL) and in FD
and RFT.inconspicuous bony structures; optical analysis of the X-ray
diagnosed a “normal/healthy” jawbone. The lower X-ray in
Figure 6 shows the dimension of the contrast agent filling
up the FDOJ after curetting of FDOJ, which was not ad-
equately recorded by the X-ray before surgery. The
right columns compare RANTES expression for this
FDOJ area (RFT #47) with RANTES in HJB (n = 19).
Case report: recurring breast cancer and comparison of
RANTES overexpression in the wisdom tooth area and in
the jawbone underneath a root-filled tooth
The patient, 69 years old, had recurring BC on the right
side. This case is of interest because of the difference in
RANTES expression in the jawbone underneath end-
odontically treated tooth #46 (US #30) and in retromolar
area #48/49 (US #32). In Figure 7, X-rays show the
inconspicuous apical area of RFT #46 with only very
discrete changes in the trabecular structures. The columns
in the same figure compare the distribution of seven cyto-
kines in this FDOJ sample (in red) and 19 healthy controls
(in blue). The X-rays in Figure 8 show the inconspicuous
retromolar wisdom tooth area #48/49. As in Figure 7, the
columns in Figure 8 compare the distribution of seven cy-
tokines in the FDOJ sample of wisdom tooth area #48/49
(in red) and in 19 healthy controls (in blue). Amazingly,
RANTES expression in area #46 underneath the RFT was
threefold higher (6,178 pg/mL) than RANTES expression
in area #48/49 (only 2,060 pg/mL), with obvious IWH in
the former area of WTS. Please note again the comprehen-









OJ (n = 16) from the jawbones of a group of patients with SYD
27.6 195.5 101.0 7.5 20.3 11 149.9








Figure 6 Comparison of seven cytokines in FDOJ underneath RFT #47 with the cytokines in the healthy jawbone (n= 19). Intraoperative documentation
of extension of FDOJ in the right lower jawbone, area #47 apically of RFT #47, by contrast agent after the surgical removal of RFT #47.
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Role of RANTES in inflammatory disease
RANTES belongs to the family of chemotactic cytokines
known as CC pattern chemokines. It is expressed by an
early response gene. RANTES is chemotactic for T-cells,27.6
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Apical area of RFT
2D-OPG                      3D-cone bea
Figure 7 Comparison of the seven cytokines in the FDOJ underneath RFT
shows the apical area of RFT #46 in a red circle on a two-dimensional orth
sagittal plane in three-dimensional cone beam (3D-CB).eosinophils, and basophils, and it plays a key role in
recruiting leukocytes to inflammatory sites. The signifi-
cance of RANTES for the development of diseases
seems to be enormous; RANTES interferes with im-












#46 with the cytokines in the healthy jawbone (n = 19). The left X-ray

















WT area #48/49 in
2D-OPG                    3D-cone beam(sagittal plane) 
Figure 8 Comparison of seven cytokines in the FDOJ in area #48/49 with cytokines in a healthy jawbone (n = 19). The left X-ray shows the
retromolar WT area on a two-dimensional orthopantomogram (2D-OPG); the right X-ray shows the same area in the sagittal plane in
three-dimensional cone beam (3D-CB).
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tic properties of RANTES send T-cells, dendritic cells,
eosinophils, natural killer (NK) cells, mast cells, and ba-
sophils to the sites of inflammation and infection [8].
RANTES is also an effective activator of leukocytes,
which play a key role in a wide range of inflammatory
disorders [9] (i.e., in RA) [10]. The role of RANTES as a
key mediator in RA is well known in medical science;
RANTES is secreted by human fibroblasts in the synovia
and therefore can be part of a progressive inflammatory
process that accompanies RA [11]. RA is characterized
by the recruitment of leukocytes from the vasculature
into inflamed synovial tissue and synovial fluid, which
depends, in part, upon the continued maintenance of
chemotactic stimuli. The selective chemoattractant and
activation effects of chemokines on leucocytes identify
them as potentially ideal candidates for mediating select-
ive inflammatory processes in RA [12].
In their studies, other researchers have demonstrated
that by expressing RANTES and IL-8, synovial fibro-
blasts may participate in the ongoing inflammatory
process in RA. In addition, the observation that the gene
coding for these chemokines is differentially regulated,
depending upon the presence of different cytokines, in-
dicates that the type of cellular infiltrate and the pro-
gress of the inflammatory disease is likely to depend
upon the relative levels of stimulatory and inhibitory cy-
tokines [10]. Synoviocytes produce synovial fluid andsecrete many of these effector molecules, which advance
inflammation and joint destruction [13]. They form part
of a complex network of autocrine and paracrine factors.
Wang et al. reported that there is increasing evidence
suggesting a role for RANTES in the pathogenesis of
RA, and they further evaluated the possible effect of the
RANTES gene on the susceptibility to RA in Chinese
patients. Their research indicated that a polymorphism
in the promoter region of the RANTES gene is associ-
ated with susceptibility to RA in the Chinese population
[14]. This conclusion may explain the fact that while
many people have FDOJ lesions in their jawbone, only a
certain percentage suffer from RA. Differences in genet-
ically defined susceptibility to RANTES seem to be one
factor that determines which disease—out of many con-
nected to high RANTES levels—might be induced by
signaling from FDOJ-derived RANTES.
A summary of the results of these studies provides evi-
dence that RANTES is a key mediator in all joint inflam-
mation. RANTES has also been associated with the
induction or promotion of cancer [15]. RANTES levels
were markedly elevated in the primary tumor and meta-
static lesions of all patients with breast and cervical
cancer. The high incidence and intensity of RANTES ex-
pression has been noted in advanced BC. RANTES ex-
pression was analyzed in parallel to disease progression,
which was positive upon diagnosis and was predictive of
clinical course. These results suggest that the assessment
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cator for the identification of patients with an apparently
poor prognosis [16]. The development of BC may, in
part, be due to the ability of RANTES to act directly on
the tumor cells and to promote tumor progression [17].
Origin of RANTES in FDOJ and adipocytes
That the inflammatory response of adipose tissue is as-
sociated with a systemic inflammatory response is well
known and widely discussed. In obesity, this systemic in-
flammatory response originates in the adipose tissue
itself. Secretion of inflammatory cytokines mediates the
systemic effects of adipose tissue inflammation. Huber
et al. found an increased expression of RANTES in fatty
tissue in obese patients [18]. Our findings regarding
RANTES/CCL5 secretion by FDOJ deserve further dis-
cussion: reduced blood flow and capillary density
followed by ischemia in the jawbone may lead to a hyp-
oxic situation [19]. Adipocytes and the necrotic parts of
fat cells are considered by many studies to be immuno-
logically effective ingredients. The role of these immune
effects on understanding FDOJ, RANTES/CCL5, and
SYD is an evident issue and needs further illumination
in the discussion. While proinflammatory cytokines such
as TNF-α, IL-6, and prostaglandins are already distrib-
uted early in the acute stage of an injury or tissue infec-
tion, there are many indications that chemokines like
RANTES are activated at a later time and that they can
act in the conversion of acute pain into a more chronic
phenomenon. In fact, recent data suggest that, in con-
junction with tissue damage or infection, ischemia-
induced chemokine expression causes an increase in
inflammatory cytokines [20].
FDOJ as a systemic threat from RANTES overexpression
FDOJ is similar to silent inflammation or subclinical in-
flammation without typical signs of acute inflammation.
In CI, the local production of proinflammatory cytokines
overstrains regulatory and compensating mechanisms by
building FDOJ in the bone marrow. This phenomenon
seems to be more widespread than dentists and doctors
presumed in the past. It is generally accepted that an im-
balance between cytokines and their specific inhibitors is
characteristic of chronic inflammatory conditions [21].
Cytokines merge to release the immune response and to
induce acute inflammatory events in the transition or
persistence of the CI. This means that when maintaining
healthy conditions, the cytokine-producing mechanisms
must be controlled [22]. FDOJ represents a new cellular
response phenomenon in inflammation, in that the cyto-
kines are not released bacterially or virally, but by per-
sisting metabolic derailments in the medullary space of
the jawbone. If the body does not succeed in revising the
metabolic disturbances in the IWH area of the jawbonewithin a certain period, increasing numbers of immune
cells are recruited in the fatty tissue. The chronically
silent inflammation of the medullary fatty tissue leads
to the local development of proinflammatory signal-
ing mediators—in particular, RANTES/CCL5. These
systemically affect the organism and can result in
chronic inflammatory processes or provoke further
pathophysiological mechanisms.
The problem of diagnosing FDOJ lesions by X-ray
In earlier research, we already demonstrated the nonvisi-
bility and lack of radiographic appearance of FDOJ,
which makes it difficult to obtain an accurate diagnosis
by common dental radiographic means [23]. Thus, the
existence of FDOJ is largely neglected today in main-
stream dentistry, as is its systemic relevance. The reason
for this is that conventional X-ray techniques are limited
in their ability to reveal the actual extent and location of
FDOJ. To aid the practitioner in diagnosing the debilitat-
ing effects of bone marrow softening inside FDOJ
lesions, a computer-assisted through transalveolar ultra-
sound (TAU) device is available [24]. TAU precisely im-
ages and identifies cavitational porosity in the jawbone.
TAU imaging proved significantly superior to radiology
for the detection of microscopically confirmed FDOJ.
The efficiency and reliability of TAU in the diagnosis
and imaging of FDOJ has been presented in numerous
publications [25]. Because of these diagnostic difficulties,
jawbone disease is underdiagnosed by dentists in general
and, consequently, by doctors in SYD cases. The missing
coincidence between inconspicuous X-rays and the over-
expression of proinflammatory signaling pathways in
corresponding FDOJ areas—as shown in Figures 6, 7,
and 8—lends this phenomenon importance in the dis-
cussion about “silent inflammation”.
Conclusions
In our eyes, this is one of the first investigations to show
a potential correlation between RA (of any type) and is-
chemic or inflammatory jawbone lesions—an association
that has been speculated on for decades. Additionally,
chemokine overexpression in the jawbone connected to
RFT seems to be a possible danger for immune preserva-
tion, which is needed to maintain a balanced system and
to prevent different types of SYD. IWH in old extraction
sites and underneath RFT might also provoke immune
modulation, which hinders the restoration of an already
disease-modified immune system. The presence of cyto-
kine imbalances in the jawbone leads to internal signal-
ing through the accessory pathways via overexpressed
RANTES/CCL5, which can lead to chronic pathologies
such as cancer, diabetes, and cardiovascular diseases in
the long term, as well as neurodegenerative or inflam-
matory processes. Once a chronic disease has been
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ered “silent inflammation” in the jawbone progressively
creates a set of pathological conditions that worsens the
overall condition and leads to further deficiencies. It is a
vicious circle. This is the reason why restoring a modi-
fied system might require synergistic actions at the den-
tal level, including surgical curettage of FDOJ or the
elimination of RF with additional cleaning of the sur-
rounding jawbone. Thus, dentists can help to not only
alleviate the symptoms of acute inflammation but also
put their patients on track to avoid the devastating ef-
fects of CI, which exists below the threshold of perceived
pain and can smolder silently for decades. Novel thera-
peutic strategies that specifically target the inflammatory
reaction in FDOJ could considerably contribute to the
reduction of morbidity in patients. A more critical atti-
tude inside the dental community to wound healing after
dental surgery is a potential clinical implementation of
the achieved results. The actual paper follows recom-
mendations of the “EPMA White Paper” [26].
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